Belvedere Trading
BDTX icon

Belvedere Trading’s Black Diamond Therapeutics BDTX Stock Holding History

Belvedere Trading’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$28.1K – 702
2023
Q4 		$28.1K Hold
10,000
– – ﹤0.01% 620
2023
Q3 		$28.7K Buy
+10,000
New +$36.8K ﹤0.01% 474

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Belvedere Trading's BDTX Position: Q4 2023 in Review

Belvedere Trading sold out of Black Diamond Therapeutics (BDTX) in Q4 2023, closing a stake of 980 shares — an estimated $2.3K sold.

Belvedere Trading first reported a position in BDTX in Q4 2022 and held it in 2 quarters. The position peaked at $31.1K in Q4 2022. 76 funds tracked by Wall St. Rank hold BDTX as of Q4 2023.

  • Belvedere Trading reported no remaining Black Diamond Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Belvedere Trading sold 980 Black Diamond Therapeutics shares in Q4 2023, an estimated $2.3K.
  • Belvedere Trading first reported a position in Black Diamond Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belvedere Trading's Black Diamond Therapeutics position peaked at $31.1K in Q4 2022.
  • 76 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.